This website is for Israeli Healthcare Professionals only

Dear Doctor,

As hematologists, ensuring patients receive their treatments correctly and on schedule is crucial for positive outcomes. We understand the challenges of managing complex dosing regimens amidst busy clinical workflows.

That's why Abbvie developed a dedicated assistant tool for the dosing schedule of Epcoritamab (Tepkinly).

Simply enter the initial dose date, and the assistant will automatically generate the complete planned treatment calendar. If a dose is missed or delayed, input the requested information, and the tool will recalculate the new dosing schedule, including instructions for repriming in case it is needed.

 

We encourage you to take advantage of this digital solution.

Before using the tool, it is important that you read the disclaimers at the bottom of this page.

1. This calculator is intended for the use of health care professionals only and it is meant as a scheduling assistant for the treatment with Epcoritamab. The tool is based on the Israeli Tepkinly prescribing information.

2. As per AbbVie’s privacy policy, no information of any sort is collected when utilizing this website or tool.

3. In case you choose to print any of the tool’s output, we advise you to label the information with the patient’s hospital sticker after printing so it can be assigned to the specific patient for which the dosing schedule has been planned.

4. In case you choose to save the information as PDF, we advise you to label the information when saving so it can be assigned to the specific patient for which the dosing schedule has been planned.

5. For safety reports, medical inquiries or product quality complaints please contact us at: pvisrael@abbvie.com

 

For the full prescribing information of Tepkinly please refer to the Tepkinly prescribing information.

 

 

EPCO-IL-00001-MC. Date of preparation: May 2024.

A re-priming Cycle (identical to Cycle 1 with standard CRS prophylaxis) is required in one of the following cases:        

If there are more than 8 days between the priming dose (0.16 mg) and intermediate dose (0.8mg), or

If there are more than 14 days between the intermediate dose (0.8 mg) and first full dose (48 mg), or

If there are more than 6 weeks between full doses (48 mg)

After the re-priming cycle, the patient should resume treatment with Day 1 of the next planned treatment cycle (subsequent to the cycle during which the dose was delayed).